Loading…
Loading…
COPHF (Creso Pharma Limited) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
COPHF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for COPHF and 80,000+ other tickers.
See exactly how COPHF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for COPHF and 80,000+ other tickers.
Creso Pharma Limited is a global pharmaceutical company focused on the development, registration, and commercialization of advanced cannabis and hemp-based solutions. These therapeutic products and nutraceuticals are designed for both human and animal health applications, with market presence spanning Europe, the Middle East, North America, and the Asia Pacific region. Beyond innovative product creation, the company also manages the cultivation, processing, and distribution of cannabis products, extending its reach to the retail sector. Its diverse portfolio includes specialized offerings…
Shares of Melodiol Global Health Limited (OTCMKTS:COPHF – Free Report) are set to reverse split before the market opens on Wednesday, June 5th. The 1-30 reverse split was announced on Wednesday, June 5th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, June 5th. Melodiol Global Health Stock Performance Melodiol Global Health stock opened at $0.00 on Monday. The business has a 50 day simple moving average of $0.01 and a 200 day simple moving average of $0.02. Melodiol Global Health has a one year low of $0.00 and a one year high of $9.47. Melodiol Global Health Company Profile (Get Free Report) Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products.
The Secure and Fair Enforcement (SAFE) Banking Act made headlines again this week as it was the focus of a Senate committee hearing on marijuana banking challenges. Typically any progress on this game-changing legislation for US cannabis businesses is welcomed by investors, sending cannabis stocks higher, but this week it appeared to have the opposite effect.
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) (Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF), Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)) subsidiary Halucenex Life Sciences Inc will expand the scope of Phase 2 clinical trials assessing the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD). If the amendment to the trial's Clinical Trial Authorisation (CTA) is granted by Health Canada, Halucenex will be able to include cohorts being treated with Selective Serotonin Reuptake Inhibitors (SSRIs) without requiring these patients to cease their prescribed medications a week prior to the trial.
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a list of companies that can provide psychedelic compounds to researchers and patients under the SAP.
Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Colorado-based consumer packaged goods company, Sierra Sage Herbs, LLC. Under the agreement and subject to shareholder approval, Creso Pharma, via its wholly-owned subsidiary, Creso Pharma US, Inc, will purchase a 100% interest in SSH for a total upfront consideration of $21 million, payable by the issue of fully paid ordinary shares, based on the 10-day volume-weighted average price at the date of execution of the agreement, being $0.083, and the AUD/USD exchange rate as at the date of closing.